Author:
Areechokchai Darin,Bowonwatanuwong Chureeratana,Phonrat Benjaluck,Pitisuttithum Punnee,Maek-a-Nantawat Wirach
Abstract
Background
The use of antiretroviral drugs (ARV) to prevent mother-to-child HIV transmission (PMTCT) promises to be effective. However, limited data on the adverse effects of ARV among pregnant women and pregnancy outcomes have been reported in clinical practice.
Objectives
This study aimed to assess adverse effects and outcomes among pregnant HIV-infected women receiving antiretroviral drugs for either antiretroviral therapy (ART) or PMTCT.
Study Design
This cohort study was at Chonburi Hospital, Thailand, in 2002-2006.
Results
A total of 246 pregnant HIV-infected women with the median age (range) of 27 (16-41) years were included in this study. ART was initiated in 16.3% for treatment during ANC, 66.7% for PMTCT during ANC, and 17.1% for PMTCT in labor. Adverse effects, especially anemia, were significantly associated with continuing combined ART in pregnancy (p<0.001). 88.9% delivered normal-term neonates. The prevalence of pre-term delivery was 10.2%. Overall, 24 adverse events from 21 pregnant women (8.5%) were noted. A significantly higher prevalence of pre-term delivery was noted in the groups continuing combined ART, or initiating of PMTCT during labor rather than ANC (p=0.02). The incidence of low Apgar scores was 3.6%, and these were associated with initiation of PMTCT during labor (p=0.004).
Conclusion
Adverse ARV events were more numerous among the pregnant women who needed ART than PMTCT. ANC is beneficial and strongly recommended for all pregnant HIV-infected women for better pregnancy outcomes.
Publisher
Bentham Science Publishers Ltd.
Subject
Virology,Infectious Diseases,Public Health, Environmental and Occupational Health
Reference19 articles.
1. Connor EM, Sperling RS, Gelber R, et al.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
N Engl J Med
1994;
331
: 1173-80.
2. Lorenzi P, Spicher VM, Laubereau B, et al.
Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study
AIDS
1998;
12
: F241-7.
3. Suy A, Martínez E, Coll O, et al.
Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy
AIDS
2006;
20
: 59-66.
4. Hitti J, Frenkel LM, Stek AM, et al.
Maternal toxicity with continuous nevirapine in pregnancy results from PACTG 1022
J Acquir Immune Defic Syndr
2004;
36
: 772-6.
5. Perinatal HIV Guidelines Working Group, USA Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [monograph on the internet].
Department of Health and Human Services
Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf
2006
[cited 2008 Sep 6];